EA201270618A1 - Способ предотвращения кристаллизации лекарственных веществ в полимерной пленке - Google Patents

Способ предотвращения кристаллизации лекарственных веществ в полимерной пленке

Info

Publication number
EA201270618A1
EA201270618A1 EA201270618A EA201270618A EA201270618A1 EA 201270618 A1 EA201270618 A1 EA 201270618A1 EA 201270618 A EA201270618 A EA 201270618A EA 201270618 A EA201270618 A EA 201270618A EA 201270618 A1 EA201270618 A1 EA 201270618A1
Authority
EA
Eurasian Patent Office
Prior art keywords
preventing crystallization
drug substance
polymeric film
medicinal substances
polymer film
Prior art date
Application number
EA201270618A
Other languages
English (en)
Other versions
EA025301B1 (ru
Inventor
Йоханнес Ёзеф Леонхард
Вальтер Мюллер
Original Assignee
Лтс Ломанн Тэрапи-Зистеме Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43877347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201270618(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Лтс Ломанн Тэрапи-Зистеме Аг filed Critical Лтс Ломанн Тэрапи-Зистеме Аг
Publication of EA201270618A1 publication Critical patent/EA201270618A1/ru
Publication of EA025301B1 publication Critical patent/EA025301B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)

Abstract

Настоящее изобретение касается способа предотвращения кристаллизации лекарственного вещества в полимерной пленке, в котором распределяемое, содержащее растворитель наносимое покрытие для получения полимерной пленки, содержащее один полимер, образующий матрицу, или смесь полимеров и по меньшей мере одно лекарственное вещество, временно высушивают при температурах, которые по меньшей мере на 10°С выше температуры плавления лекарственного вещества, содержащегося в наносимом покрытии. Таким образом, необходима более высокая, чем для обычного высушивания, максимальная температура и не требуется дополнительный, требующий дополнительного времени и затрат производственный этап.
EA201270618A 2009-11-12 2010-10-26 Способ предотвращения кристаллизации лекарственных веществ в полимерной пленке EA025301B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009052972A DE102009052972A1 (de) 2009-11-12 2009-11-12 Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
PCT/EP2010/006535 WO2011057714A2 (de) 2009-11-12 2010-10-26 Verfahren zur verhinderung der kristallisation von arzneistoffen in einem polymerfilm

Publications (2)

Publication Number Publication Date
EA201270618A1 true EA201270618A1 (ru) 2013-01-30
EA025301B1 EA025301B1 (ru) 2016-12-30

Family

ID=43877347

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270618A EA025301B1 (ru) 2009-11-12 2010-10-26 Способ предотвращения кристаллизации лекарственных веществ в полимерной пленке

Country Status (17)

Country Link
US (2) US8932665B2 (ru)
EP (1) EP2498762B1 (ru)
JP (3) JP5837883B2 (ru)
KR (1) KR101685736B1 (ru)
CN (2) CN102770128A (ru)
AR (1) AR079028A1 (ru)
AU (1) AU2010318328B2 (ru)
BR (1) BR112012011297B8 (ru)
CA (1) CA2780787C (ru)
DE (1) DE102009052972A1 (ru)
EA (1) EA025301B1 (ru)
ES (1) ES2594765T3 (ru)
IL (1) IL219674B (ru)
MX (1) MX2012005511A (ru)
PL (1) PL2498762T3 (ru)
TW (1) TWI489998B (ru)
WO (1) WO2011057714A2 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204173A1 (en) 2008-10-02 2010-08-12 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) * 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
CN103919755B (zh) * 2013-01-15 2019-10-18 江苏康倍得药业股份有限公司 妥洛特罗透皮贴剂及其制备方法
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
JP6573913B2 (ja) * 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
JP6895755B2 (ja) * 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
CN106456568B (zh) 2014-05-20 2020-03-27 Lts勒曼治疗系统股份公司 包含界面调节剂的经皮递送系统
KR102363218B1 (ko) 2017-12-19 2022-02-14 히사미쓰 세이야꾸 가부시키가이샤 로티고틴 함유 첩부제
JP7399633B2 (ja) * 2019-06-14 2023-12-18 株式会社大石膏盛堂 経皮吸収型製剤の製造方法
DE102019117870B3 (de) * 2019-07-02 2020-11-26 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm
FI3854388T3 (fi) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066534B2 (ja) 1986-10-09 1994-01-26 積水化学工業株式会社 経皮吸収貼付剤
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5662928A (en) 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
AU1120097A (en) * 1995-12-01 1997-06-27 Alza Corporation Improved method for preventing crystal formation in a dispersion of a liquid in a matrix
CA2302411C (en) * 1997-09-02 2007-01-30 Novartis Ag Improved method for preventing crystal formation in a scopolamine transdermal device
DE19954936A1 (de) 1999-11-16 2001-05-17 Bayer Ag Verfahren zur Herstellung von Benzofuranonoximen
DE60008136T2 (de) 1999-11-23 2004-09-09 Aderis Pharmaceuticals, Inc. Verbessertes verfahren zur herstellung von n-substituierte aminotetraline
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
ES2203563T3 (es) 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
JP4641394B2 (ja) 2004-08-06 2011-03-02 リンテック株式会社 経皮吸収型製剤の製造方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
US8344165B2 (en) 2007-05-30 2013-01-01 Chemagis Ltd. Crystalline rotigotine base and preparation process therefor
WO2009053697A1 (en) 2007-10-26 2009-04-30 Pliva Hrvatska D.O.O. Polymorphic forms of ( s ) -rotigotine hydrochloride
WO2009063171A1 (en) 2007-11-16 2009-05-22 Pliva Hrvatska D.O.O. Novel rotigotine salts
EP2215072B1 (en) 2007-11-28 2015-09-02 UCB Pharma GmbH Polymorphic form of rotigotine
US20110087042A1 (en) * 2008-02-04 2011-04-14 Matrix Laboratories Limited Crystalline oxybutynin and process for preparing the same
IT1392387B1 (it) 2008-09-26 2012-03-02 Solmag S P A Ora Fidia Farmaceutici S P A Processo per la preparazione di rotigotina
AU2009302853B2 (en) 2008-10-06 2014-09-11 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
WO2010073124A2 (en) 2008-12-26 2010-07-01 Actavis Group Ptc Ehf Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie

Also Published As

Publication number Publication date
BR112012011297B8 (pt) 2021-05-25
AU2010318328B2 (en) 2015-01-22
JP6161668B2 (ja) 2017-07-12
CN106619578A (zh) 2017-05-10
EP2498762A2 (de) 2012-09-19
DE102009052972A1 (de) 2011-09-15
US8932665B2 (en) 2015-01-13
IL219674A0 (en) 2012-07-31
AR079028A1 (es) 2011-12-21
JP5837883B2 (ja) 2015-12-24
US20120213912A1 (en) 2012-08-23
CA2780787C (en) 2017-11-07
JP2017149758A (ja) 2017-08-31
ES2594765T3 (es) 2016-12-22
WO2011057714A2 (de) 2011-05-19
JP6374566B2 (ja) 2018-08-15
MX2012005511A (es) 2012-06-14
CN102770128A (zh) 2012-11-07
CA2780787A1 (en) 2011-05-19
US20140046279A1 (en) 2014-02-13
KR20120115258A (ko) 2012-10-17
JP2016028078A (ja) 2016-02-25
JP2013510805A (ja) 2013-03-28
IL219674B (en) 2018-10-31
TWI489998B (zh) 2015-07-01
BR112012011297A2 (pt) 2016-04-12
BR112012011297B1 (pt) 2020-12-15
CN106619578B (zh) 2021-10-01
EP2498762B1 (de) 2016-09-07
WO2011057714A3 (de) 2011-07-07
EA025301B1 (ru) 2016-12-30
US9408809B2 (en) 2016-08-09
PL2498762T3 (pl) 2017-02-28
AU2010318328A1 (en) 2012-05-31
TW201124156A (en) 2011-07-16
KR101685736B1 (ko) 2016-12-12

Similar Documents

Publication Publication Date Title
EA201270618A1 (ru) Способ предотвращения кристаллизации лекарственных веществ в полимерной пленке
ATE456563T1 (de) Neue mit cyclohexylresten substituierte1,4- benzothiepin-1,1 -dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
BR112014019823A8 (pt) Composição de resina curável, resina curada, material compósito, e, métodos para fabricar uma parte de compósito e para fabricar um prepreg
ATE493136T1 (de) Neues einstufiges verfahren zur herstellung von vernetzten poly(allylamin)-polymeren
BRPI0909997A2 (pt) r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
EA201290499A1 (ru) Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами
BRPI0916550A2 (pt) composições compreendendo intensificadores de doçura e métodos de produção das mesmas
MA33778B1 (fr) Marquage modifié à base de polymères cristaux liquides chiraux
BR112012013653A2 (pt) marcação baseada em polímeros de cristais líquidos quirais
CY1110115T1 (el) Παραγωγα ακετυλενυλο-πυραζολο-πυριμιδινης ως mglur2 ανταγωνιστες
ATE517621T1 (de) Verwendung von ampk-aktivierenden imidazol- derivaten, herstellungsverfahren dafür und diese enthaltende pharmazeutische zusammensetzungen
DE602006019979D1 (de) Neues zwischenprodukt zur herstellung von montelukast und verwandten verbindungen
CL2007002969A1 (es) Procedimiento para producir producto poroso en polvo a partir de un producto inicial pulverulento y/o viscoso que comprende llevar el producto inicial a un estado viscoso, disminuir viscosidad sin cambiar % de materia seca, simultaneamente iniciar po
DK2114386T3 (da) Farmaceutisk sammensætning til behandling af diabeteskomplikationer
ATE482194T1 (de) Indolonderivate, verfahren zu deren herstellung und deren anwendungen
EA201170772A1 (ru) Органические соединения
MA33777B1 (fr) Marquage de polymères cristaux liquides chiraux
ATE416758T1 (de) Niedertemperatur-trocknungsverfahren zur herstellung von arzneimittelhaltigen polymerzusammensetzungen
BR112015021620A2 (pt) método para a fabricação de um elemento sensor eletrolítico para a detecção de pelo menos uma propriedade de um gás de medição em uma câmara de gás de medição, contendo duas camadas cerâmicas porosas
MX2016003523A (es) Composiciones de materiales de recubrimiento y recubrimientos curables a baja temperatura producidos a partir de las mismas, y su utilizacion.
FR2936798B1 (fr) Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
EA200971106A1 (ru) Соединения с семичленным кольцом и их фармацевтические применения для предупреждения и лечения диабета и метаболического синдрома
MY167777A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
DE602008006421D1 (de) Verfahren zur Herstellung von organischen polymerischen Profilen
CL2014000819A1 (es) Compuestos heterociclicos derivados de etinilo, moduladores alostericos mglur5; proceso de preparacion; composicion farmaceutica; uso en la prevencion o el tratamiento de esquizofrenia, enfermedades cognitivas, sindrome de la x fragil o autismo.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM